PTC Therapeutics, Inc. Commenced A Rolling Submission Of A New Dr
PTC Therapeutics, Inc. (NASDAQ:PTCT) had announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration (FDA) for the treatment of nonsense mutation Duchenne muscular dystrophy. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing…